Cancer Therapeutics, Inc. is a biotechnology business incubator, with a specific emphasis on disruptive treatments and nanotechnology.  It seeks out disruptive cancer research and technology opportunities to invest in, develop, and commercialize.  The end result will be therapies, treatments, and pharmaceuticals targeted at more efficiently and effectively attacking cancer.  CTI seeks partners to co-develop drugs in various stages in our pipeline.

CTI’s first investment under this strategy is NanoTherapies LLC.  Nano’s products introduce disruptive technology into the treatment and detection of cancer through the use of calcium phosphate nanoparticles.  These particles, about 350 times smaller than a human cell, provide both a safe and effective way to transport drugs and imaging materials into diseased cells.  The compatibility of the calcium phosphate nanoparticle with the biomechanics of the human body makes it unique for application in the treatment of diseases.  Patient benefits from drugs jacketed with calcium phosphate nanoparticles are immense.

The development of these life-changing therapies for cancer treatment is achieved through an evolving set of intellectual properties and patents derived from the exploitation of calcium phosphate nanoparticles for therapeutic and diagnostic applications.  NanoTherapies has sole license and patent protection for the fundamental use of calcium phosphate nanoparticles in medical applications for the treatment and detection of blood cancers (all forms of leukemia).  Nano also owns all rights to manufacturing technologies and patents required to produce pharmaceutical quality drugs at the scale and yield needed for commercial viability.

Four drugs have been identified for accelerated market delivery and early revenue:  Methotrexate, Cytarabine, Fludarabine and Daunorubicin.  Cerimide-based drugs and a newly discovered Amplified Photon Emission Therapy (APET) also comprise part of the product portfolio, but will require longer clinical trials to get to market.

Cancer Therapeutics will be in a position to engage high level personnel and intellectual capital from NanoTherapies to evaluate other synergistic investment opportunities.  CTI will then pursue the most promising and valuable technologies to reach the market expeditiously and benefit the lives of cancer patients worldwide.

Cancer Therapeutics Inc is a Delaware corporation.  CTI’s Common Stock is listed on the NASD Electronic Bulletin Board under the symbol “CTHP.”  The Company’s stock has been traded on the Bulletin Board since March, 2007.